CL2014000736A1 - Proteina de fusion que comprende una variante de fgf21 y una region fc. - Google Patents

Proteina de fusion que comprende una variante de fgf21 y una region fc.

Info

Publication number
CL2014000736A1
CL2014000736A1 CL2014000736A CL2014000736A CL2014000736A1 CL 2014000736 A1 CL2014000736 A1 CL 2014000736A1 CL 2014000736 A CL2014000736 A CL 2014000736A CL 2014000736 A CL2014000736 A CL 2014000736A CL 2014000736 A1 CL2014000736 A1 CL 2014000736A1
Authority
CL
Chile
Prior art keywords
fgf21
variant
region
fusion protein
fusion
Prior art date
Application number
CL2014000736A
Other languages
English (en)
Inventor
R Boettcher Brian
S Daniels Douglas
Hamamatsu Norio
Licht Stuart
Craig Weldon Stephen
L Caplan Shari
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014000736A1 publication Critical patent/CL2014000736A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2014000736A 2011-09-26 2014-03-25 Proteina de fusion que comprende una variante de fgf21 y una region fc. CL2014000736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
CL2014000736A1 true CL2014000736A1 (es) 2014-10-03

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000736A CL2014000736A1 (es) 2011-09-26 2014-03-25 Proteina de fusion que comprende una variante de fgf21 y una region fc.
CL2016002215A CL2016002215A1 (es) 2011-09-26 2016-09-02 Proteina de fusion que comprende una variante del factor de crecimiento de fibroblastos 21 (fgf21) y una region fc, polinucleotido, vector, celula huesped; metodo para producir la proteina de fusion y composicion farmaceutica (divisional de sol. n° 736-14).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016002215A CL2016002215A1 (es) 2011-09-26 2016-09-02 Proteina de fusion que comprende una variante del factor de crecimiento de fibroblastos 21 (fgf21) y una region fc, polinucleotido, vector, celula huesped; metodo para producir la proteina de fusion y composicion farmaceutica (divisional de sol. n° 736-14).

Country Status (41)

Country Link
US (6) US9006400B2 (es)
EP (2) EP2760475B1 (es)
JP (4) JP6186361B2 (es)
KR (1) KR102085605B1 (es)
CN (2) CN107266579B (es)
AP (1) AP2014007543A0 (es)
AR (2) AR088044A1 (es)
AU (1) AU2012316052A1 (es)
BR (1) BR112014007069B1 (es)
CA (1) CA2849464C (es)
CL (2) CL2014000736A1 (es)
CO (1) CO6920257A2 (es)
CR (1) CR20140140A (es)
CU (2) CU24314B1 (es)
CY (2) CY1120928T1 (es)
DK (2) DK3321276T3 (es)
EA (1) EA039633B1 (es)
ES (2) ES2689762T3 (es)
GT (1) GT201400055A (es)
HR (2) HRP20211575T1 (es)
HU (2) HUE039857T2 (es)
IL (1) IL231533B (es)
IN (1) IN2014DN02043A (es)
JO (1) JO3476B1 (es)
LT (2) LT3321276T (es)
MA (1) MA35437B1 (es)
MX (1) MX350273B (es)
MY (1) MY166059A (es)
PE (2) PE20141551A1 (es)
PL (2) PL3321276T3 (es)
PT (2) PT2760475T (es)
RS (2) RS62341B1 (es)
SG (2) SG11201400538QA (es)
SI (2) SI2760475T1 (es)
SM (1) SMT202100595T1 (es)
TN (1) TN2014000109A1 (es)
TW (1) TWI593708B (es)
UA (1) UA113856C2 (es)
UY (2) UY34346A (es)
WO (1) WO2013049247A1 (es)
ZA (1) ZA201401700B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012542A2 (en) 2006-07-25 2008-01-31 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2835607C (en) 2011-07-01 2021-07-20 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
KR102724421B1 (ko) 2012-12-27 2024-10-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
LT3097122T (lt) 2014-01-24 2020-07-27 Ngm Biopharmaceuticals, Inc. Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai
EP3125921B1 (en) * 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10517929B2 (en) * 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Fgf21變異體
WO2017201527A2 (en) * 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
US11318186B2 (en) 2016-05-25 2022-05-03 Board Of Regents, The University Of Texas System Use of FGF21 in methods of increasing exocrine pancreatic secretion
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技(上海)有限公司 用于构建融合蛋白的连接肽
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技(上海)有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
EP3558341A1 (en) 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
US11479591B2 (en) 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
SMT202400277T1 (it) * 2017-12-22 2024-09-16 Novartis Ag Trattamento di disturbi metabolici con varianti di fgf21
EP3749683A4 (en) 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230060422A1 (en) 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR20230034357A (ko) * 2020-07-02 2023-03-09 사노피 Glp-1r 작용제/fgf21 융합 단백질
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトfgf−21遺伝子および遺伝子発現産物
JP2003535037A (ja) 1999-12-23 2003-11-25 ザイモジェネティクス,インコーポレイティド 炎症を治療する方法
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
EP1702067A1 (en) * 2003-12-10 2006-09-20 Eli Lilly And Company Muteins of fibroblast growth factor 21
PL1751184T3 (pl) * 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
BRPI0514790A (pt) * 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
ES2477543T3 (es) 2008-10-24 2014-07-17 Irm Llc Pirrolina-carboxi-lisina generada biosintéticamente y modificaciones de proteínas específicas de sitio mediante derivatización química de restos de pirrolina-carboxi-lisina y pirrolisina
CA2760674A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
PL3248610T3 (pl) * 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy

Also Published As

Publication number Publication date
WO2013049247A1 (en) 2013-04-04
US20150166622A1 (en) 2015-06-18
MX350273B (es) 2017-08-31
UY34346A (es) 2013-04-30
CL2016002215A1 (es) 2016-10-28
TW201326213A (zh) 2013-07-01
HUE055584T2 (hu) 2021-12-28
AU2012316052A1 (en) 2014-04-17
PE20141551A1 (es) 2014-10-26
HK1251238A1 (en) 2019-01-25
EP3321276A3 (en) 2018-06-20
JP2018023370A (ja) 2018-02-15
US20160193297A1 (en) 2016-07-07
JP2020007314A (ja) 2020-01-16
TN2014000109A1 (en) 2015-07-01
CY1124697T1 (el) 2022-07-22
IL231533B (en) 2018-06-28
JP6186361B2 (ja) 2017-08-23
RS62341B1 (sr) 2021-10-29
CN103945871B (zh) 2017-04-26
EA201490695A1 (ru) 2015-10-30
HRP20181558T1 (hr) 2018-11-30
PL3321276T3 (pl) 2022-01-17
JO3476B1 (ar) 2020-07-05
ES2895080T3 (es) 2022-02-17
US20130079500A1 (en) 2013-03-28
EP2760475A1 (en) 2014-08-06
CN107266579A (zh) 2017-10-20
US9266935B2 (en) 2016-02-23
MA35437B1 (fr) 2014-09-01
EA039633B1 (ru) 2022-02-18
CU24314B1 (es) 2018-02-08
HUE039857T2 (hu) 2019-02-28
EP2760475B1 (en) 2018-07-04
ES2689762T3 (es) 2018-11-15
ZA201401700B (en) 2015-01-28
IN2014DN02043A (es) 2015-05-15
TWI593708B (zh) 2017-08-01
MY166059A (en) 2018-05-22
AR123908A2 (es) 2023-01-25
US11129874B2 (en) 2021-09-28
AP2014007543A0 (en) 2014-03-31
HRP20211575T1 (hr) 2022-02-04
US20180369332A1 (en) 2018-12-27
CN103945871A (zh) 2014-07-23
JP2022058546A (ja) 2022-04-12
BR112014007069A2 (pt) 2017-03-28
DK2760475T3 (en) 2018-10-15
CU20150171A7 (es) 2016-07-29
GT201400055A (es) 2017-09-28
UA113856C2 (xx) 2017-03-27
DK3321276T3 (da) 2021-10-25
PL2760475T3 (pl) 2018-11-30
SG11201400538QA (en) 2014-06-27
CA2849464A1 (en) 2013-04-04
KR102085605B1 (ko) 2020-03-06
CY1120928T1 (el) 2019-12-11
CU24206B1 (es) 2016-10-28
PE20181159A1 (es) 2018-07-19
PT2760475T (pt) 2018-10-25
CO6920257A2 (es) 2014-04-10
CN107266579B (zh) 2022-07-12
IL231533A0 (en) 2014-04-30
AR088044A1 (es) 2014-05-07
JP2014534172A (ja) 2014-12-18
US11944664B2 (en) 2024-04-02
RS57868B1 (sr) 2018-12-31
US20240261372A1 (en) 2024-08-08
PT3321276T (pt) 2021-10-27
SG10201602339XA (en) 2016-05-30
JP6567613B2 (ja) 2019-08-28
BR112014007069B1 (pt) 2020-12-15
LT3321276T (lt) 2021-11-10
US10076554B2 (en) 2018-09-18
CR20140140A (es) 2014-07-15
MX2014003677A (es) 2014-04-30
CU20140034A7 (es) 2014-08-28
US9006400B2 (en) 2015-04-14
KR20140069250A (ko) 2014-06-09
UY39119A (es) 2021-04-30
US20210386824A1 (en) 2021-12-16
SI3321276T1 (sl) 2021-11-30
JP7339372B2 (ja) 2023-09-05
LT2760475T (lt) 2018-10-25
SI2760475T1 (sl) 2018-10-30
CA2849464C (en) 2024-01-30
EP3321276A2 (en) 2018-05-16
SMT202100595T1 (it) 2022-01-10
EP3321276B1 (en) 2021-07-28
NZ622998A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
CL2014000736A1 (es) Proteina de fusion que comprende una variante de fgf21 y una region fc.
CL2014000737A1 (es) Proteina de fusion de funcion dual que comprende una region agonista del receptor de glp-1 y una region agonista del receptor de fgf21.
CL2014000195A1 (es) Proteina de fusion que comprende un primer y segundo dominio asociados a una señal positiva y a una señal negativa respectivamente; metodo para tratar paciente con cancer que comprende tratar con dicha proteina.
CL2014001193A1 (es) Proteina de fusion que es un anticuerpo bi-específico con especifidad por ox40 humano y a albúmina de suero humano.
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
BR112013018317A2 (pt) mutantes de fc do anticorpo resistentes a protease ativa
EP2403941A4 (en) REVERSE TRANSCRIPTASE FUSION PROTEINS STABILIZED
CO7020851A2 (es) Proteínas y péptidos modificados
EP2943512A4 (en) BOVINE FUSION ANTIBODY
UY34017A (es) Proteínas de fusión y vacunas de combinación
CL2016000219A1 (es) Proteinas de fusión terapéutica.
BR112013028892A2 (pt) proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
SMT201700025T1 (it) Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
EP2906602A4 (en) LYSINE-SPECIFIC LYSINE-SPECIFIC TRANSCRIPTIONING ACTIVATOR (TALE) - DEMETHYLASE-1 FUSION PROTEINS (LSD1)
BRPI0919346A2 (pt) lente oftálmica energizada.
EP2753635A4 (en) P53-ACTIVATING PEPTIDES
BR112013022279A2 (pt) proteína de fusão induzível anti-angiogênico e o seu uso
HRP20181690T1 (hr) Varijante protutijela fc
EP2697369A4 (en) NOVEL METHODS FOR PURIFYING PROTEINS
HUE043273T2 (hu) Fúziós fehérje
EP2545080A4 (en) NPP1 FUSION PROTEINS
CL2015003496A1 (es) Anticuerpos teicoicos anti-pared y conjugados.
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
IL226205A0 (en) Anticancer fusion protein
EP2698386A4 (en) FUSION PROTEIN